

ASX / Media Release

14 January 2011

---

## RHT: FerriScan<sup>®</sup> Reimbursement Update

Resonance Health has received notification from the Medical Services Advisory Committee (MSAC) at the Department of Health and Ageing in Australia regarding the Company's application for public funding for FerriScan.

MSAC have declined to provide funding for FerriScan at this time. However, MSAC have encouraged the Company to submit a new condensed application to address some specific information requirements. The company plans to collect and resubmit this additional information to MSAC by the middle of 2011.

FerriScan is an MRI test providing an accurate assessment of iron overload and is currently used within Australia to optimise iron chelation therapy, a treatment used to remove excess iron from the body which results from regular blood transfusions. FerriScan is also being used in Australia to assist in the management of patients with hereditary haemochromatosis.

FerriScan currently receives public funding in several international jurisdictions and this response from MSAC is disappointing and a setback for patients with iron overload in Australia. The company remains committed to providing equitable access to FerriScan, an effective non-invasive monitoring tool of the body iron burden for patients with iron overload.

Within the United States, gaining access to insurance funding for FerriScan is being progressed. A Health Technology Assessment (HTA) of FerriScan was completed in Q4 2010. Meetings with private insurance payers are planned for Q1 2011 and the company looks forward to providing an update on US insurance coverage decisions to its shareholders and other stakeholders this year.

By Order of the Board  
Resonance Health Limited

For further information please contact:

**Resonance Health**

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

Colin McDonald  
Company Secretary  
T: +61 8 9286 5300  
E: [colinm@ferriscan.com](mailto:colinm@ferriscan.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.